logo
Twitter
Discord
Email
logo
DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc.

NASDAQ•DMAC
CEO: Mr. Dietrich John Pauls MBA
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2012-08-03
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Contact Information
301 Carlson Parkway, Suite 210, Minneapolis, MN, 55305, United States
(763)-496-5454
www.diamedica.com
Market Cap
$394.49M
P/E (TTM)
-11.8
38.2
Dividend Yield
--
52W High
$10.42
52W Low
$3.19
52W Range
61%
Rank62Top 92.6%
1.9
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.17+13.33%
4-Quarter Trend

FCF

-$6.62M+47.82%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Cash Position Strengthened Combined cash, equivalents, and securities total $55.3M as of September 30, 2025, up from $44.1M year-end 2024.
July Private Placement Closed Raised $30.0M net proceeds in July 2025 private placement, funding operations and clinical expansion efforts.
PE Trial Interim Results Investigator-sponsored PE Phase 2 Part 1a showed DM199 safe, well-tolerated with sustained blood pressure reduction.

Risk Factors

Operating Cash Burn Widens Net cash used in operating activities increased to $(21.3)M for nine months 2025 versus $(15.6)M prior year.
AIS Trial Enrollment Slow ReMEDy2 trial faces slower site activations and enrollment due to staffing shortages and protocol complexity.
Significant Future Capital Needed Expect substantial additional capital required to complete required clinical studies and achieve commercialization milestones.

Outlook

Key Clinical Milestones Targeted Planning FPI for PE Part 1b in 1H 2026; anticipating AIS ReMEDy2 interim analysis in 2H 2026.
R&D Spending Expected Rise R&D expenses expected to moderately increase as DM199 program advances into PE and global ReMEDy2 expansion.
ATM Offering Available $98.4M remains available under the August 2025 At-The-Market offering program for future capital needs.

Peer Comparison

Revenue (TTM)

DiaMedica Therapeutics Inc.DMAC
$13.80M
-55.2%
Humacyte, Inc.HUMA
$8.80M
-18.5%
Replimune Group, Inc.REPL
$1.47M
-63.6%

Gross Margin (Latest Quarter)

Humacyte, Inc.HUMA
65.5%
+0.0pp
Candel Therapeutics, Inc.CADL
0.0%
+0.0pp
Alpha Tau Medical Ltd.DRTS
0.0%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
DRTS$607.08M-14.9-56.5%12.9%
REPL$552.22M-2.1-82.8%19.6%
DSGN$528.62M-7.8-30.6%0.8%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 16, 2026
|
EPS:-$0.17
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 12, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.17+13.3%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 12, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.18+38.5%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 13, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.18+28.6%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 17, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.60+0.0%
    N/A

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 13, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.15+25.0%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 7, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.13-18.8%
    N/A

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 8, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.14-30.0%
    N/A

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 19, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.60-15.4%
    N/A